Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.41 |
| ▸ | PRKACA | P17612 | 2/20 | 0.41 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.39 |
| ▸ | NMT2 | O60551 | 1/20 | 0.37 |
| ▸ | NMT1 | P30419 | 1/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | GNPAT | O15228 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26426329 | 0.86 | QRFPR (0.42) | ALBSIRT5TLR2ROCK2PRKACA | |
| SCHEMBL10027319 | 0.86 | MEN1 (0.52) | ALBSIRT5TLR2ROCK2PRKACA | |
| SCHEMBL18174546 | 0.85 | ALB (0.49) | ALBSIRT5TLR2ROCK2PRKACA | |
| SCHEMBL14902998 | 0.85 | CASP2 (0.51) | ALBSIRT5TLR2NOD1SIRT6 | |
| SCHEMBL24461841 | 0.85 | ALB (0.49) | ALBSIRT5TLR2ROCK2PRKACA | |
| SCHEMBL878812 | 0.84 | SIRT5 (0.44) | ALBSIRT5TLR2ROCK2PRKACA | |
| SCHEMBL10130532 | 0.84 | SIRT5 (0.60) | ALBSIRT5TLR2ROCK2PRKACA | |
| SCHEMBL16285431 | 0.81 | SIRT5 (0.53) | ALBSIRT5TLR2ROCK2PRKACA | |
| SCHEMBL30440181 | 0.81 | ALB (0.48) | ALBSIRT5TLR2ROCK2PRKACA | |
| SCHEMBL31626331 | 0.81 | ALB (0.48) | ALBSIRT5TLR2ROCK2PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9534032-B2 | Thrombopoietic compounds | AMGEN INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-9145450-B2 | Thrombopoietic compounds | AMGEN INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150024431-A1 | THROMBOPOIETIC COMPOUNDS | AMGEN INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-8748571-B2 | Thrombopoietic compounds | AMGEN INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120208760-A1 | THROMBOPOIETIC COMPOUNDS | AMGEN INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120034657-A1 | THROMBOPOIETIC COMPOUNDS | AMGEN INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150024431-A1 | THROMBOPOIETIC COMPOUNDS | MPL, THPO, PDGFA | ALB 2993/4885SIRT5 1934/4885TLR2 3064/4885 |
| US-20120208760-A1 | THROMBOPOIETIC COMPOUNDS | MPL, THPO, PDGFA | ALB 2993/4885SIRT5 1934/4885TLR2 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.